

**Amended Claims**

Cl. 25 (twice amended) A pharmaceutical preparation for activating an immune response comprising

a conjugate of an antigen and a neonatal Fc receptor ("FcRn") binding partner, wherein the antigen is selected from the group consisting of:

an antigen that [is characteristic of] elicits an immune response to a pathogen, and

an antigen that [is characteristic of] elicits an immune response to a tumor; and

a pharmaceutically-acceptable carrier, wherein the preparation is formulated as a unit dosage containing the conjugate in an amount effective for activating the immune response of a mammal when administered to an apical surface of an epithelial barrier of the mammal, and wherein the pharmaceutical preparation is an oral formulation, an aerosol formulation or a nasal formulation.